Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

The high efficacy of muscarinic M4 receptor in D1 medium spiny neurons reverses striatal hyperdopaminergia.

Nair AG, Castro LRV, El Khoury M, Gorgievski V, Giros B, Tzavara ET, Hellgren-Kotaleski J, Vincent P.

Neuropharmacology. 2019 Mar 1;146:74-83. doi: 10.1016/j.neuropharm.2018.11.029. Epub 2018 Nov 22.

PMID:
30468798
2.

Antidepressive effects of targeting ELK-1 signal transduction.

Apazoglou K, Farley S, Gorgievski V, Belzeaux R, Lopez JP, Grenier J, Ibrahim EC, El Khoury MA, Tse YC, Mongredien R, Barbé A, de Macedo CEA, Jaworski W, Bochereau A, Orrico A, Isingrini E, Guinaudie C, Mikasova L, Louis F, Gautron S, Groc L, Massaad C, Yildirim F, Vialou V, Dumas S, Marti F, Mechawar N, Morice E, Wong TP, Caboche J, Turecki G, Giros B, Tzavara ET.

Nat Med. 2018 May;24(5):591-597. doi: 10.1038/s41591-018-0011-0. Epub 2018 May 7.

PMID:
29736027
3.

Structural and Functional Characterization of the Interaction of Snapin with the Dopamine Transporter: Differential Modulation of Psychostimulant Actions.

Erdozain AM, De Gois S, Bernard V, Gorgievski V, Pietrancosta N, Dumas S, Macedo CE, Vanhoutte P, Ortega JE, Meana JJ, Tzavara ET, Vialou V, Giros B.

Neuropsychopharmacology. 2018 Apr;43(5):1041-1051. doi: 10.1038/npp.2017.217. Epub 2017 Sep 14.

PMID:
28905875
4.

Dopamine Transporter and Reward Anticipation in a Dimensional Perspective: A Multimodal Brain Imaging Study.

Dubol M, Trichard C, Leroy C, Sandu AL, Rahim M, Granger B, Tzavara ET, Karila L, Martinot JL, Artiges E.

Neuropsychopharmacology. 2018 Mar;43(4):820-827. doi: 10.1038/npp.2017.183. Epub 2017 Aug 22.

5.

Amygdala and regional volumes in treatment-resistant versus nontreatment-resistant depression patients.

Sandu AL, Artiges E, Galinowski A, Gallarda T, Bellivier F, Lemaitre H, Granger B, Ringuenet D, Tzavara ET, Martinot JL, Paillère Martinot ML.

Depress Anxiety. 2017 Nov;34(11):1065-1071. doi: 10.1002/da.22675. Epub 2017 Aug 9.

PMID:
28792656
6.

Striatal and Extrastriatal Dopamine Transporter Availability in Schizophrenia and Its Clinical Correlates: A Voxel-Based and High-Resolution PET Study.

Artiges E, Leroy C, Dubol M, Prat M, Pepin A, Mabondo A, de Beaurepaire R, Beaufils B, Korwin JP, Galinowski A, D'Albis MA, Santiago-Ribeiro MJ, Granger B, Tzavara ET, Martinot JL, Trichard C.

Schizophr Bull. 2017 Sep 1;43(5):1134-1142. doi: 10.1093/schbul/sbw192.

7.

Paraquat Induces Peripheral Myelin Disruption and Locomotor Defects: Crosstalk with LXR and Wnt Pathways.

Hichor M, Sampathkumar NK, Montanaro J, Borderie D, Petit PX, Gorgievski V, Tzavara ET, Eid AA, Charbonnier F, Grenier J, Massaad C.

Antioxid Redox Signal. 2017 Jul 20;27(3):168-183. doi: 10.1089/ars.2016.6711. Epub 2016 Dec 19.

PMID:
27788593
8.

Liver X receptors alpha and beta promote myelination and remyelination in the cerebellum.

Meffre D, Shackleford G, Hichor M, Gorgievski V, Tzavara ET, Trousson A, Ghoumari AM, Deboux C, Nait Oumesmar B, Liere P, Schumacher M, Baulieu EE, Charbonnier F, Grenier J, Massaad C.

Proc Natl Acad Sci U S A. 2015 Jun 16;112(24):7587-92. doi: 10.1073/pnas.1424951112. Epub 2015 May 28.

9.

In vivo occupancy of dopamine D3 receptors by antagonists produces neurochemical and behavioral effects of potential relevance to attention-deficit-hyperactivity disorder.

Barth V, Need AB, Tzavara ET, Giros B, Overshiner C, Gleason SD, Wade M, Johansson AM, Perry K, Nomikos GG, Witkin JM.

J Pharmacol Exp Ther. 2013 Feb;344(2):501-10. doi: 10.1124/jpet.112.198895. Epub 2012 Nov 29.

PMID:
23197772
10.

Interactions between the cannabinoid and dopaminergic systems: evidence from animal studies.

El Khoury MA, Gorgievski V, Moutsimilli L, Giros B, Tzavara ET.

Prog Neuropsychopharmacol Biol Psychiatry. 2012 Jul 2;38(1):36-50. doi: 10.1016/j.pnpbp.2011.12.005. Epub 2012 Jan 20. Review.

PMID:
22300746
11.

Antidepressant-like effects of an AMPA receptor potentiator under a chronic mild stress paradigm.

Farley S, Apazoglou K, Witkin JM, Giros B, Tzavara ET.

Int J Neuropsychopharmacol. 2010 Oct;13(9):1207-18. doi: 10.1017/S1461145709991076. Epub 2010 Jan 11.

PMID:
20059803
12.

Individual differences in the effects of cannabinoids on motor activity, dopaminergic activity and DARPP-32 phosphorylation in distinct regions of the brain.

Polissidis A, Chouliara O, Galanopoulos A, Rentesi G, Dosi M, Hyphantis T, Marselos M, Papadopoulou-Daifoti Z, Nomikos GG, Spyraki C, Tzavara ET, Antoniou K.

Int J Neuropsychopharmacol. 2010 Oct;13(9):1175-91. doi: 10.1017/S1461145709991003. Epub 2009 Nov 27.

PMID:
19941698
13.

CB1 receptor knockout mice are hyporesponsive to the behavior-stimulating actions of d-amphetamine: role of mGlu5 receptors.

Tzavara ET, Degroot A, Wade MR, Davis RJ, Nomikos GG.

Eur Neuropsychopharmacol. 2009 Mar;19(3):196-204. doi: 10.1016/j.euroneuro.2008.11.003. Epub 2008 Dec 29.

PMID:
19116182
14.

Role of metabotropic glutamate receptor 5 in the procholinergic effects of neuropsychotherapeutic compounds.

Tzavara ET, Wade MR, Davis RJ, El Khoury MA, Nomikos GG.

Synapse. 2008 Dec;62(12):940-3. doi: 10.1002/syn.20560.

PMID:
18798268
15.

The vesicular glutamate transporter VGLUT3 synergizes striatal acetylcholine tone.

Gras C, Amilhon B, Lepicard EM, Poirel O, Vinatier J, Herbin M, Dumas S, Tzavara ET, Wade MR, Nomikos GG, Hanoun N, Saurini F, Kemel ML, Gasnier B, Giros B, El Mestikawy S.

Nat Neurosci. 2008 Mar;11(3):292-300. doi: 10.1038/nn2052. Epub 2008 Feb 17.

PMID:
18278042
16.

Association between the PPP3CC gene, coding for the calcineurin gamma catalytic subunit, and bipolar disorder.

Mathieu F, Miot S, Etain B, El Khoury MA, Chevalier F, Bellivier F, Leboyer M, Giros B, Tzavara ET.

Behav Brain Funct. 2008 Jan 17;4:2. doi: 10.1186/1744-9081-4-2.

17.

Antipsychotics increase vesicular glutamate transporter 2 (VGLUT2) expression in thalamolimbic pathways.

Moutsimilli L, Farley S, El Khoury MA, Chamot C, Sibarita JB, Racine V, El Mestikawy S, Mathieu F, Dumas S, Giros B, Tzavara ET.

Neuropharmacology. 2008 Mar;54(3):497-508. Epub 2007 Nov 17.

PMID:
18155072
18.

Chronic valproate normalizes behavior in mice overexpressing calcineurin.

Herzog CJ, Miot S, Mansuy IM, Giros B, Tzavara ET.

Eur J Pharmacol. 2008 Feb 2;580(1-2):153-60. Epub 2007 Oct 25.

PMID:
18021766
19.

Functional alterations of nicotinic neurotransmission in dopamine transporter knock-out mice.

Weiss S, Tzavara ET, Davis RJ, Nomikos GG, Michael McIntosh J, Giros B, Martres MP.

Neuropharmacology. 2007 Jun;52(7):1496-508. Epub 2007 Feb 24.

PMID:
17433376
20.

Biochemical and behavioral evidence for antidepressant-like effects of 5-HT6 receptor stimulation.

Svenningsson P, Tzavara ET, Qi H, Carruthers R, Witkin JM, Nomikos GG, Greengard P.

J Neurosci. 2007 Apr 11;27(15):4201-9.

21.

Calcineurin (protein phosphatase 2B) is involved in the mechanisms of action of antidepressants.

Crozatier C, Farley S, Mansuy IM, Dumas S, Giros B, Tzavara ET.

Neuroscience. 2007 Feb 23;144(4):1470-6. Epub 2007 Jan 4.

PMID:
17207580
22.

The procholinergic effects of the atypical antipsychotic olanzapine are independent of muscarinic autoreceptor inhibition.

Tzavara ET, Bymaster FP, Nomikos GG.

Mol Psychiatry. 2006 Jul;11(7):619-21. No abstract available.

PMID:
16801977
23.

Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A beta antibody.

Bales KR, Tzavara ET, Wu S, Wade MR, Bymaster FP, Paul SM, Nomikos GG.

J Clin Invest. 2006 Mar;116(3):825-32. Epub 2006 Feb 23.

24.

A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders.

Witkin JM, Tzavara ET, Davis RJ, Li X, Nomikos GG.

Trends Pharmacol Sci. 2005 Dec;26(12):609-17. Epub 2005 Nov 2.

PMID:
16260047
25.

Procholinergic and memory enhancing properties of the selective norepinephrine uptake inhibitor atomoxetine.

Tzavara ET, Bymaster FP, Overshiner CD, Davis RJ, Perry KW, Wolff M, McKinzie DL, Witkin JM, Nomikos GG.

Mol Psychiatry. 2006 Feb;11(2):187-95.

PMID:
16231039
26.

Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications.

Tzavara ET, Li DL, Moutsimilli L, Bisogno T, Di Marzo V, Phebus LA, Nomikos GG, Giros B.

Biol Psychiatry. 2006 Mar 15;59(6):508-15. Epub 2005 Sep 30.

PMID:
16199010
27.

A role for cannabinoid CB1 receptors in mood and anxiety disorders.

Witkin JM, Tzavara ET, Nomikos GG.

Behav Pharmacol. 2005 Sep;16(5-6):315-31. Review.

PMID:
16148437
28.

Selective cortical VGLUT1 increase as a marker for antidepressant activity.

Moutsimilli L, Farley S, Dumas S, El Mestikawy S, Giros B, Tzavara ET.

Neuropharmacology. 2005 Nov;49(6):890-900. Epub 2005 Aug 18.

PMID:
16111724
29.

Mesolimbic dopamine super-sensitivity in melanin-concentrating hormone-1 receptor-deficient mice.

Smith DG, Tzavara ET, Shaw J, Luecke S, Wade M, Davis R, Salhoff C, Nomikos GG, Gehlert DR.

J Neurosci. 2005 Jan 26;25(4):914-22.

30.

M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related CNS pathologies.

Tzavara ET, Bymaster FP, Davis RJ, Wade MR, Perry KW, Wess J, McKinzie DL, Felder C, Nomikos GG.

FASEB J. 2004 Sep;18(12):1410-2. Epub 2004 Jul 1.

PMID:
15231726
31.

Exposure to an elevated platform increases plasma corticosterone and hippocampal acetylcholine in the rat: reversal by chlordiazepoxide.

Degroot A, Wade M, Salhoff C, Davis RJ, Tzavara ET, Nomikos GG.

Eur J Pharmacol. 2004 Jun 16;493(1-3):103-9.

PMID:
15189770
32.

Cannabinoids reduce cAMP levels in the striatum of freely moving rats: an in vivo microdialysis study.

Wade MR, Tzavara ET, Nomikos GG.

Brain Res. 2004 Apr 16;1005(1-2):117-23.

PMID:
15044071
33.

Diverse psychotomimetics act through a common signaling pathway.

Svenningsson P, Tzavara ET, Carruthers R, Rachleff I, Wattler S, Nehls M, McKinzie DL, Fienberg AA, Nomikos GG, Greengard P.

Science. 2003 Nov 21;302(5649):1412-5.

34.
35.

Dysregulated hippocampal acetylcholine neurotransmission and impaired cognition in M2, M4 and M2/M4 muscarinic receptor knockout mice.

Tzavara ET, Bymaster FP, Felder CC, Wade M, Gomeza J, Wess J, McKinzie DL, Nomikos GG.

Mol Psychiatry. 2003 Jul;8(7):673-9.

PMID:
12874603
36.

The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions.

Tzavara ET, Davis RJ, Perry KW, Li X, Salhoff C, Bymaster FP, Witkin JM, Nomikos GG.

Br J Pharmacol. 2003 Feb;138(4):544-53.

37.

Nicotine withdrawal syndrome: behavioural distress and selective up-regulation of the cyclic AMP pathway in the amygdala.

Tzavara ET, Monory K, Hanoune J, Nomikos GG.

Eur J Neurosci. 2002 Jul;16(1):149-53.

PMID:
12153540
38.

Novel, not adenylyl cyclase-coupled cannabinoid binding site in cerebellum of mice.

Monory K, Tzavara ET, Lexime J, Ledent C, Parmentier M, Borsodi A, Hanoune J.

Biochem Biophys Res Commun. 2002 Mar 22;292(1):231-5.

PMID:
11890697
39.

DARPP-32 mediates serotonergic neurotransmission in the forebrain.

Svenningsson P, Tzavara ET, Liu F, Fienberg AA, Nomikos GG, Greengard P.

Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):3188-93.

40.

Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac).

Svenningsson P, Tzavara ET, Witkin JM, Fienberg AA, Nomikos GG, Greengard P.

Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):3182-7.

41.

The cannabinoid CB(1) receptor antagonist SR141716A increases norepinephrine outflow in the rat anterior hypothalamus.

Tzavara ET, Perry KW, Rodriguez DE, Bymaster FP, Nomikos GG.

Eur J Pharmacol. 2001 Aug 31;426(3):R3-4.

PMID:
11527547
42.

Effects of cannabinoids in Krox-24 targeted mice.

Tzavara ET, Monory K, Garel S, Topilko P, Charnay P, Hanoune J.

Neuroreport. 2001 May 25;12(7):1367-70.

PMID:
11388413
43.

Reduction of opioid dependence by the CB(1) antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction.

Mas-Nieto M, Pommier B, Tzavara ET, Caneparo A, Da Nascimento S, Le Fur G, Roques BP, Noble F.

Br J Pharmacol. 2001 Apr;132(8):1809-16.

44.

Cannabinoid withdrawal is dependent upon PKA activation in the cerebellum.

Tzavara ET, Valjent E, Firmo C, Mas M, Beslot F, Defer N, Roques BP, Hanoune J, Maldonado R.

Eur J Neurosci. 2000 Mar;12(3):1038-46.

PMID:
10762335
45.

Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with delta-9-tetrahydrocannabinol.

Hutcheson DM, Tzavara ET, Smadja C, Valjent E, Roques BP, Hanoune J, Maldonado R.

Br J Pharmacol. 1998 Dec;125(7):1567-77.

46.

Diurnal variation of the adenylyl cyclase type 1 in the rat pineal gland.

Tzavara ET, Pouille Y, Defer N, Hanoune J.

Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):11208-12.

Supplemental Content

Loading ...
Support Center